Pharmaceutical News

RSS

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc., has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Market Authorization Application (MAA) with the European Medicines Agency (EMA) for voclosporin, under the proposed brand name, LUVENIQ(TM).

4 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

"Knowledge deficit" about methadone responsible for resulting deaths

In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids.

4 Feb 2010

Expert available to discuss Lancet’s retraction of paper on autism study

Rae Sonnenmeier, clinical associate professor of communication sciences and disorders at the University of New Hampshire and staff member at UNH's Institute on Disability, is available to discuss the announcement yesterday (Feb. 2, 2010) by the medical journal The Lancet regarding the retraction of a paper that caused a 12-year international battle over the links between the three-in-one childhood vaccine MMR (measles, mumps, rubella) and autism.

4 Feb 2010

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).

4 Feb 2010

February issue of Chest releases latest medical news

Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD.

4 Feb 2010

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Pharma IQ, a division of IQPC, announces that Kevin O’Donnell Director & CTA of Tegrant Corporation and Chair of IATA’s Time & Temperature Task Force will discuss compliance with IATA’s revised Chapter 17 at the 8th Cold Chain Management and Temperature Control Summit.

From IQPC Ltd 4 Feb 2010

Health Canada accepts AbstralTM New Drug Submission for review

Orexo AB today confirms that its partner, ProStrakan Group plc has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.

4 Feb 2010

Paracetamol reduces damage caused to kidneys following severe muscle injury

The commonly-used painkiller Paracetamol can protect against kidney failure after severe muscle injury, according to research at the University of Essex.

4 Feb 2010

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Providing preventive Tamiflu and educating and emphasizing the need for repeated hand sanitizer use and disinfectant spray helped stop the spread of H1N1 influenza at a boys' summer camp in northern Alabama, according the co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

4 Feb 2010

Sermo announces a new report on evolving trends in CML

Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.

4 Feb 2010

New discovery lays foundation for development of new anti-HIV drugs

A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS.

4 Feb 2010

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.

4 Feb 2010

CRN issues statement on "The Dietary Supplement Safety Act of 2010"

The responsible dietary supplement industry represents the health and wellness interests of more than 150 million Americans who use dietary supplements each year. The number one priority for CRN and our members is to ensure that our consumers have access to safe, beneficial products that they can incorporate into their daily wellness regimens.

4 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Vaccination against seasonal influenza produces protective immune response in infants

Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.

4 Feb 2010